Editorial comment: The concept that androgens affect the male erectile response has long been considered although incompletely de®ned. Possible regulatory roles for androgens in penile erection physiology have been mostly studied in the rat with focus given to the hemodynamic characteristics and nitric oxide neurotransmission involved in erectile responses. However, generalizations regarding androgen control in the erection physiology of other mammalian species remain uncertain. More importantly, the exact molecular mechanism of androgen action in erectile function has not been described. Using the rabbit model, these investigators evaluated the consequences of androgen deprivation (castration) and androgen replacement (testosterone administration following castration) on a range of regulatory features concerning penile erection: intracavernosal hemodynamics in vivo and alpha 1 -adrenoceptor expression, neuronal nitric oxide synthase (nNOS) expression and activity, phosphodiesterase type 5 activity, and smooth muscle amount in isolated corpus cavernosal tissue. Androgen dependence was shown for nerve-stimulated intracavernosal pressures, alpha 1 -adrenoceptor content in corpus cavernosal tissue, and corpus cavernosal smooth muscle integrity. Androgen levels had no particular effect on nNOS biochemical measurements in the corpus cavernosum. Androgen replacement produced an increased biochemical measurement of phosphodiesterase type 5 in the corpus cavernosum. The sum of these ®ndings indicates that androgen deprivation causes functional andaor structural changes in the corpus cavernosum unrelated to adrenergic or nNOS-based mechanisms, at least in the rabbit, that affect penile erection. Further investigations are still needed to resolve the mechanism(s) of androgen action in the regulation of penile erection. Editorial comment: The very recent application of gene transfer techniques involving some basic modulators of penile erection to improve erectile responses in animal models has opened up new directions for gene therapy in the ®eld of erection physiology. The emphasis of the discovery of nitric oxide (NO) mediation of penile erections has centered mainly on the neuronal isoform of NO synthase (NOS), which synthesizes NO, while overlooking the potential erectogenic importance of endothelial NOS (eNOS), which also synthesizes NO. Taking a special interest in the eNOS isoform for a gene therapy strategy, these investigators have applied an adenovirus vector for eNOS to assess whether it can be overexpressed in the aged rat penis to improve erectile responses. The investigation found that the adenovirus vector did transfer eNOS successfully to the aged rat corpus cavernosum according to biochemical measurement and this eNOS gene expression was functionally relevant in increasing intracavernosal pressures in response to pharmacologic and electrical nerve stimulation in vivo. Additionally, biochemically assayed corpus cavernosal cGMP levels were increased, while erections were further enhanced following the administration of a type 5 phosphodiesterase inhibitor, verifying that this gene transfer resulted in the activation of known signal transduction mechanisms. The results lend important support for the functional prominence of eNOS in the regulation of erectile function, and they establish that the in vivo gene transfer of eNOS could constitute a meaningful therapeutic intervention for the treatment of erectile dysfunction. This successful application of gene therapy is certain to prompt further consideration of similar strategies that pertain to multiple possible regulatory factors involved in penile erection. Editorial comment: The nitric oxideacyclic guanosine monophosphate (cGMP) signalling cascade has been well established as the main functional control system for penile erection. However, the molecular targets that are activated by cGMP and ultimately execute penile smooth muscle relaxation, fundamentally required for erectile function, are not precisely known. The role of cyclic adenosine monophosphate (cAMP)-dependent signal transduction mechanisms, either as a requisite regulatory mechanism or as an alternate control system, in the physiology of penile erection is also unclear. These investigators have identi®ed a cGMP-dependent protein kinase subtype termed cGKI with apparent functional effects on vascular and intestinal smooth muscle, hypothesizing that this molecular site could represent the de®nitive receptor mediating the action of cGMP in erectile tissue. Their investigation employed genetically engineered mice lacking cGKI that underwent immunohistochemical studies of their erectile tissue and functional experiments pertaining to their erectile ability. There were no differences between the mutant cGKI-de®cient mice and their wild-type counterparts in erectile tissue nerve populations and neurotransmitter content thought to be relevant for erectile responses. The mutant mice showed extremely poor ability to copulate, and isolated corpus cavernosal tissue preparations from these animals failed to relax under typical nitric oxide stimulatory conditions. Forskolin, which stimulates adenylate cyclase and increases the intracellular concentration of cAMP, elicited equivalent relaxant effects in mutant and normal corpus cavernosal tissue, indicating that the cAMP-dependent signal transduction pathway is unaffected by the lack of cGKI. This investigation determines a requisite role of cGKI in the regulatory aspects of erectile function, as a downstream component of the nitric oxideacGMP signalling cascade. It also reveals that cAMP-dependent mechanisms, while functionally operative in the penis, do not exert primary or compensatory roles in the regulation of penile erection. Consequently, the importance of nitric oxide in the physiology of penile erection is reaf®rmed, overcoming doubts that have been drawn from observations of retained erectile function exhibited by apparently neuronal nitric oxide synthase-de®cient transgenic mice. This description of cGKI in the mouse corpus cavernosum suggests a new molecular target that can be potentially explored for pharmacotherapeutic purposes in the treatment of erectile dysfunction.
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